RESUMEN
Objective@#To observe the clinical efficacy of leuprorelin combined with mifepristone in the treatment of endometriosis.@*Methods@#From September 2014 to September 2016, 168 cases of endometriosis were selected in the research.The patients were divided into the control group and the research group according to the random number table method, with 84 patients in each group.All patients underwent laparoscopic endometrial debridement with fertility preservation.The control group was treated with mifepristone, while the study group was treated with combination of leuprorelin and mifepristone.The incidence of adverse drug reactions during treatment was observed, the levels of serum E2, LH, FSH, EmAb and CA125 were detected before and after treatment, the curative effect after treatment was evaluated, and the recurrence and pregnancy of endometriosis within 12 months after treatment were followed.@*Results@#During the treatment, the incidence rate of adverse drug reactions in the study group(17/84, 20.24%) had no statistically significant difference compared with the control group (13/84, 15.48%) (χ2=0.649, P=0.420). The levels of serum estradiol (E2), luteinizing hormone (LH), follicle stimulating hormone (FSH), anti-endometrial antibody (EmAb) and carbohydrate antigen 125 (CA125) in the two groups were significantly lower than those before treatment (t=17.694, 13.271, 7.943, 4.315, 10.029, 7.952, 14.231, 10.610, 27.953, 22.436, all P<0.001), and the indicators in the study group were significantly lower than those in the control group (t=5.217, 3.859, 3.526, 4.337, 6.048, all P<0.001). The total effective rate of the study group (96.43%) was significantly higher than that of the control group (83.33%) (χ2=7.919, P=0.005). Within 12 months after treatment, the recurrence rate of endometriosis in the study group (2.38%) was significantly lower than that of the control group (15.48%), while the rate of pregnancy (48.81%) was significantly higher than that of the control group(27.38%), there were statistically significant differences between the two groups (χ2=8.858, 8.178; P=0.003, 0.004).@*Conclusion@#Compared with leuprorelin treatment alone, leuprorelin combined with mifepristone can significantly reduce the serum levels of E2, LH, FSH, EmAb and CA125 in patients with endometriosis, and improve the overall treatment of endometriosis, reduce recurrence, promote pregnancy, and has high safety.
RESUMEN
To observe the clinical efficacy of leuprorelin combined with mifepristone in the treatment of endometriosis.Methods From September 2014 to September 2016,168 cases of endometriosis were selected in the research.The patients were divided into the control group and the research group according to the random number table method,with 84 patients in each group.All patients underwent laparoscopic endometrial debride-ment with fertility preservation.The control group was treated with mifepristone ,while the study group was treated with combination of leuprorelin and mifepristone.The incidence of adverse drug reactions during treatment was observed , the levels of serum E2,LH,FSH,EmAb and CA125 were detected before and after treatment ,the curative effect after treatment was evaluated,and the recurrence and pregnancy of endometriosis within 12 months after treatment were followed.Results During the treatment,the incidence rate of adverse drug reactions in the study group (17／84, 20.24%) had no statistically significant difference compared with the control group (13／84,15.48%) (χ2 ＝0.649, P＝0.420).The levels of serum estradiol (E2),luteinizing hormone (LH),follicle stimulating hormone (FSH),anti-endometrial antibody (EmAb) and carbohydrate antigen 125 (CA125) in the two groups were significantly lower than those before treatment (t＝17.694,13.271,7.943,4.315,10.029,7.952,14.231,10.610,27.953,22.436,all P＜0.001),and the indicators in the study group were significantly lower than those in the control group (t＝5.217, 3.859,3.526,4.337,6.048,all P＜0.001).The total effective rate of the study group (96.43%) was significantly higher than that of the control group (83.33%) ( χ2 ＝7.919,P＝0.005).Within 12 months after treatment,the recurrence rate of endometriosis in the study group (2.38%) was significantly lower than that of the control group (15.48%), while the rate of pregnancy ( 48.81%) was significantly higher than that of the control group (27.38%),there were statistically significant differences between the two groups (χ2 ＝8.858,8.178;P＝0.003, 0.004).Conclusion Compared with leuprorelin treatment alone , leuprorelin combined with mifepristone can significantly reduce the serum levels of E2,LH,FSH,EmAb and CA125 in patients with endometriosis,and improve the overall treatment of endometriosis ,reduce recurrence,promote pregnancy,and has high safety.
RESUMEN
Objective To evaluate the efficacy and safety of domestic human recombinant FSH (rhFSH) in women with anovulation of WHO groupⅡ. Methods A randomized, blind, parallel-controlled, non-inferiority and multicenter study was performed. A total of 534 admitted to 13 hospitals from May 2008 to August 2009. There were 531 women with ovulatory disorder was included in the statistical analysis, were randomly divided into test group (domestic rhFSH, n=352) and control group (imported rhFSH, n=179). Percentage of cycle with mature follicle, ovulation rate, clinical pregnancy rate, multiple pregnancy rate, ovarian hyperstimulation syndrome (OHSS) and adverse events were observed. Results No statistical significant differences (P>0.05) were observed between the two groups in terms of the efficiency on mature follicle [91.8%(323/352) versus 88.8%(159/179)], ovulation rate [91.3%(295/323) verus 90.6%(144/159)], clinical pregnancy rate [19.2%(62/323) verus 18.2%(29/159)], the number of the follicles0.05), and no other adverse events were observed in test group during treatment. Conclusion Ovarian stimulation with domestic rhFSH is effective, safe and economical in women with anovulation of WHO groupⅡ.